The DEA banned a drug some opioid users called a miracle
Summary
Researchers found that SR-17018 reduced pain and avoided some opioid-related effects in mice, but the drug has not been tested in human clinical trials. The DEA placed it in Schedule I in late August, restricting research and online access, while some people who use opioids say they used it to taper off other drugs.Key Facts
- A 2017 study in the journal Cell reported that SR-17018 relieved pain in mice without causing respiratory depression.
- Researchers also found that mice developed little tolerance to SR-17018 and that it helped morphine-dependent mice reset tolerance without withdrawal symptoms.
- The University of South Florida researcher Laura Bohn says her team has been trying to prepare human clinical trials, which have not yet taken place.
- The DEA emergency-scheduled SR-17018 as a Schedule I controlled substance in late August.
- Schedule I status makes it harder for researchers to obtain, produce, ship, and study the drug.
- Before the federal scheduling, people could buy SR-17018 online because it was not a federally controlled substance.
- Some people interviewed by WIRED said they used SR-17018 to taper off 7-OH or MGM-15 and reported few or no physical withdrawal symptoms.
- There is no clinical evidence in the article that SR-17018 is effective or safe for treating opioid dependence in humans.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
